Table 3 Use of respiratory and non-respiratory medications among evaluated COPD patients (n = 180)
From: Clinical significance in COPD patients followed in a real practice
| Non-respiratory medications | N (%) |
|---|---|
| Antihypertensivesincluding diuretics | 155 (86.1% ) |
| Antidiabetics | 26 (14.5% ) |
| Platelet antiaggregants | 37 (20.5% ) |
| Antidepressants | 30 (16.6% ) |
| Analgesics | 7 (3.8% ) |
| Digitalics | 52 (28.8% ) |
| Prokinetics | 17 (9.4% ) |
| Arterial vasodilators | 32 (17.7% ) |
| Antiarrhythmics | 35 (19.4% ) |
| Hypolipidemic drugs | 39 (21.6% ) |
| Respiratory medications | N (%) |
| Short-acting β 2 -agonists/Ipratropium | 160 (88.9% ) |
| Long-acting β 2 -agonists | 14 (7.8% ) |
| Long-acting β 2 -agonists plus inhaled corticosteroids | 162 (90% ) |
| Tiotropium | 57 (31.7% ) |
| Inhaled corticosteroids | 5 (2.8% ) |
| Methilxantines | 153 (85% ) |